Table 1.
Pathology specimens included in study
| ID | Age | Sex | Pathology group | Clinical condition | Archive time (mo) |
|---|---|---|---|---|---|
| FH1* | 43 | M | FH | HIV | 28 |
| FH2* | 14 | F | FH | RA | 26 |
| FH3* | 39 | M | FH | HIV | 24 |
| FH4* | 12 | F | FH | ALPS | 14 |
| FH5* | 52 | F | FH | RA | 13 |
| FH6* | 15 | F | FH | Hyper IgE, sepsis | 12 |
| FH7* | 13 | M | FH | Suspected ALPS | 11 |
| FH8* | 31 | F | FH | ALPS | 7 |
| FH9*,† | 64 | M | MCD | MCD | 3 |
| FH10* | 61 | F | FH | Lymphoma, remission | 3 |
| FL1† | 53 | M | FH | Lymphoma | 22 |
| FL2 | 54 | M | FL | Lymphoma | 22 |
| FL3* | 50 | M | FL | Lymphoma | 22 |
| FL4* | 50 | F | FL | Lymphoma | 21 |
| FL5* | 47 | F | FL | Lymphoma | 19 |
| FL6* | 35 | M | FL | Lymphoma | 18 |
| FL7* | 62 | F | FL | Lymphoma | 13 |
| FL8* | 68 | M | FL | Lymphoma | 13 |
| FL9* | 42 | M | FL | Lymphoma | 11 |
| FL10* | 27 | F | FL | Lymphoma | 9 |
| FL11* | 36 | F | FL | Lymphoma | 7 |
| FL12* | 54 | F | FL | Lymphoma | 2 |
Abbreviations: M, male; F, female; RA, rheumatoid arthritis; ALPS, autoimmune lymphoproliferative syndrome.
*
Matched FFPE and cryopreserved tissue.
†
Removed from DMT selection after pathology review (see text).